Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLIDE pediatric depemokimab study in eosinophilic asthma
jRCT2031260460Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of depemokimab in asthma and eosinophilic asthma (EA), sponsored by GSK. Primary endpoint: Depemokimab concentration in plasma. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
depemokimab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on jRCT2031260460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260460.